Comparison of Two Commercial Real-Time Reverse Transcriptase Polymerase Chain Reaction Assays for Porcine Reproductive and Respiratory Syndrome ­Virus

Total Page:16

File Type:pdf, Size:1020Kb

Comparison of Two Commercial Real-Time Reverse Transcriptase Polymerase Chain Reaction Assays for Porcine Reproductive and Respiratory Syndrome ­Virus Brief communication Peer reviewed Comparison of two commercial real-time reverse transcriptase polymerase chain reaction assays for porcine reproductive and respiratory syndrome virus Karen M. Harmon, PhD; Sarah A. Abate, BS; Amy J. Chriswell, BS; Wayne A. Chittick, BS; Erin L. Strait, DVM, P hD Summary Resumen - Comparación de dos pruebas Résumé - Comparaison de deux épreuves Specimens were tested for porcine reproduc- comerciales de reacción en cadena de la commerciales d’amplification en chaîne tive and respiratory syndrome virus by real- polimerasa de transcriptasa reversa en par la polymérase utilisant la transcriptase time reverse transcriptase polymerase chain tiempo real contra el virus del síndrome réverse pour détecter le virus du syndrome reaction (RT-PCR) with two commercial reproductivo y respiratorio porcino reproducteur et respiratoire porcin agent-specific assays. Result discrepancy Se examinaron muestras contra el virus del Des échantillons ont été testés pour le virus between the two tests was confirmed by síndrome reproductivo y respiratorio porcino du syndrome reproducteur et respiratoire conventional RT-PCR, sequencing, or both mediante la prueba de reacción en cadena porcin par réaction d’amplification en chaîne on six of 423 clinical cases. Neither assay de la polimerasa de transcriptasa reversa par la polymérase utilisant la transcriptase detected every positive case. (PCR-RT) en tiempo real con dos pruebas réverse (RT-PCR) avec deux épreuves spéci- comercias agente-específicas. Las discrep- fiques d’agent qui sont disponibles commer- Received: September 28, 2011 ancias entre las dos pruebas se confirmaron cialement. La non-concordance des résultats Accepted: February 27, 2012 mediante el PCR-RT convencional, secuen- entre les deux épreuves a été confirmée par ciación, ó ambos en seis de los 423 casos. RT-PCR conventionnelle, par séquençage, Ninguna de las dos pruebas detectó todos los ou par les deux techniques, pour six des 423 casos positivos. cas cliniques. Aucune des deux épreuves ne détecta tous les cas positifs. orcine reproductive and respiratory region and the primers and probes used both NA and EU subtypes. The previous syndrome virus (PRRSV) is an RNA in real-time PCR can cause false-negative version of the AB reagents (TaqMan NA 3-5 and EU PRRSV reagents) missed or weakly virus causing reproductive failure in results. Most real-time assays include detected some contemporary PRRSV strains Psows and respiratory disease in piglets and one primer pair and a single probe for each (observed and confirmed in Iowa State Uni- growing pigs.1 The high economic impact target, but to enhance the ability to detect a versity Veterinary Diagnostic Laboratory, of this agent dictates the need for rapid and genetically diverse population, it has become more common to utilize multiple primers 2010). The primers and probes were recently accurate diagnosis. Polymerase chain reac- updated to improve the assay’s detection tion (PCR) testing has been increasingly and probes in a single multiplexed assay. In this study, we compared performance of two capability. In the current study, the TC and used as a diagnostic test because of its sensi- updated AB assays were performed on a tivity and specificity and also because of the commercially available PRRSV-specific real- time reverse transcriptase PCR (RT-PCR) subset of clinical specimens submitted to the ability to complete testing the same day the Iowa State University Veterinary Diagnostic assays for detection and differentiation of sample is received. For any PCR test to be Laboratory to compare the performance of North American (NA) and European (EU) effective for determining the absence or pres- the two commercially available tests. ence of the agent of interest, it is essential subtypes of the virus. The assays are manu- that it target a highly conserved region of factured by Applied Biosystems, Foster City, California (AB), and Tetracore, Rockville, Materials and methods the genome. This is somewhat problematic The samples used in this study were ran- with RNA viruses such as PRRSV which Maryland (TC). The VetMax NA and EU PRRSV reagents (AB) and VetAlert NA and domly selected from routine case submis- have high mutation rates, resulting in rapid sions to our laboratory and consisted of 2 EU PRRSV PCR reagents (TC) each con- evolution and genetic variability. Even serum (n = 380), lung tissue (n = 277), oral tain multiple primers and probes to detect minor mismatches between the PCR target fluid (n = 245), environmental samples (n = 8), nasal swabs (n = 7), semen (n = 6), Veterinary Diagnostic Laboratory, College of Veterinary Medicine, Iowa State University, Ames, I owa. bronchoalveolar lavage fluid (n = 5), fetal th thoracic fluid (n = 4), and assorted tissues Corresponding author: Dr Karen Harmon, 1600 S 16 Street, Veterinary Diagnostic Laboratory, (n = 2). Except where noted, nucleic acid Ames, IA 50011; Tel: 515-294-1950; Fax: 515-294-3564; E-mail: [email protected] . extraction was performed using a MagMax This article is available online at http://www.aasv.org/shap.html. Viral RNA Isolation Kit (Life Technolo- Harmon KM, Abate SA, Chriswell AJ, et al. Comparison of two commercial real-time reverse gies, Carlsbad, California) in conjunction transcriptase polymerase chain reaction assays for porcine reproductive and respiratory syndrome v irus. with a Kingfisher or Kingfisher 96 J Swine Health Prod. 2012;20(4):184–188. instrument (Thermo Scientific, Waltham, 184 Journal of Swine Health and Production — July and August 2012 Massachusetts), according to the manufac- the discrepant pools were tested if sufficient of 19 of the discrepant cases were subjected turer’s recommendations. For tissue samples, sample was available. Cases that repeated to further testing by both assays, and 10 of a 10% to 20% (w/v) homogenate was as discrepant by real-time RT-PCR were these repeated as discrepant. Of those 10, six prepared using Earle’s balanced salt solution subjected to conventional RT-PCR using were lung samples, two were serum, and two and then processed on high speed for 120 primers specified by Christopher-Hennings were oral fluid. Table 1 summarizes sample seconds (Stomacher 80; Seward, Bohemia, et al7 and the Qiagen OneStep RT-PCR Kit types tested and results. The most common New York). The homogenized sample was (Qiagen Inc, Valencia, California), following observations for those that did not repeat centrifuged at approximately 4200g for 10 the manufacturer’s recommendations. Prim- as discrepant were first, the original test was minutes and the supernatant was used in ers were added at a concentration of 600 nM negative on pooled sera and positive on one the extraction procedure. Extraction of oral each, and the following thermal cycling pro- or more individual samples from the pool fluids, semen, and environmental samples file was used: 50°C for 30 minutes, 95°C for when retested (n = 3), and second, the origi- was performed as described by Chittick 15 minutes, then 35 cycles of 94°C for 30 nal Ct was lower than 36 cycles, which is 6 et al (extraction A1) except the elution seconds, 58°C for 30 seconds, and 72°C for considered weakly positive, and the original buffer volume was reduced to 50 µL. The 1 minute. A final elongation step of 72°C for result did not repeat (n = 5). One sample program used for Kingfisher extraction was 10 minutes was used. Detection of conven- had an original Ct of 28.15 only with the the Standard MagMax program provided tional RT-PCR products was performed on AB test, but upon retest was positive with by Applied Biosystems. Real-time RT-PCR a Qiaxcel (Qiagen, Inc) capillary electropho- both assays. Original and retest results of was performed on nucleic acid extracts of resis system using a DNA screening cartridge these nine cases are summarized in Table 2. a subset of samples submitted to the Iowa and method AM420. Sequencing of open Of the 10 repeating discrepant cases, nine State University Veterinary Diagnostic reading frame 5 (ORF5) was also attempted were positive by the AB assay and negative Laboratory using both VetAlert NA and EU on at least one discrepant sample from these with the TC reagents. The remaining dis- PRRSV PCR reagents (TC) and VetMax cases using forward primer 5'-AAG GTG crepant case was positive by TC and negative NA and EU PRRSV PCR reagents (AB). GTA TTT GGC AAT GTG TC-3' and by the AB assay. Reactions were performed according to reverse primer 5'-GAG GTG ATG AAT The 10 cases that repeated as discrepant were manufacturers’ instructions using the AB TTC CAG GTT TCT A-3' and the qScript subjected to additional PRRSV testing by 7500 Fast instrument. For each group of Custom One-Step RT-PCR Kit (Quanta conventional RT-PCR and ORF5 sequenc- samples, both assays were performed on the Biosciences, Gaithersburg, Maryland). ing attempts. The purpose for sequencing same day from the same nucleic-acid extract. Polymerase chain reaction setup followed was twofold: first, to confirm the presence of For the AB testing, analysis was performed the manufacturer’s recommendations, with PRRSV in the sample, and second, to deter- using the auto baseline setting. Thresholds each primer included at 320 nM and the mine relatedness of the viruses involved. for NA and EU PRRSV were set at 0.10 following cycling conditions: 48°C for 20 Five of the cases positive by the AB test and and 0.05, respectively. For TC, manual minutes, then 94°C for 3 minutes, followed negative by the TC test were confirmed baseline was used for analysis at the instru- by 45 cycles of 94°C for 30 seconds, 50°C PRRSV-positive by conventional RT-PCR. ment’s default setting of three to 15 cycles. for 50 seconds, and 68°C for 50 seconds. Two of the five also yielded complete or Thresholds for NA and EU PRRSV were set The final elongation step was 68°C for 7 partial ORF5 sequences consistent with at 51,000 and 145,000, respectively.
Recommended publications
  • Applied Biosystems 3730 and 3730Xl DNA Analyzers
    SPECIFICATION SHEET 3730 and 3730xl DNA Analyzers Applied Biosystems 3730 and 3730xl DNA Analyzers Introduction Applied Biosystems 3730 & 3730xl DNA Analyzers were developed to meet the growing needs of institutions ranging from core and research labs in academia, government, and medicine to biotechnology, pharmaceuticals, and genome centers. These high-throughput instruments couple advances in automation and optics with proprietary Applied Biosystems reagents and software to support a diverse range Key Features Key Benefits of genetic analysis projects. By • Dual-side capillary illumination • Highest-quality DNA sequencing data dramatically improving data quality, at lowest cost • Backside-thinned CCD significantly reducing total cost per – POP-7™ Polymer separation matrix sample, and enabling more runs per • Integrated auto-sampler and sample increases read length and reduces day, 3730/3730xl DNA Analyzers make plate stacker run time it quicker and easier for investigators • Onboard piercing station to get meaningful results in evolving – Multiple run modules provide options genomic applications. Whether your • Internal barcode reader for targeted length of read lab is involved in de novo sequencing, • Onboard polymer for up to 100 runs – High optical sensitivity reduces DNA resequencing, microsatellite-based and reagent consumption fragment analysis, or SNP genotyping, • Automated basecalling and quality 3730/3730xl DNA Analyzers are the value assignment – In-capillary detection consumes ideal platform for better, faster, cheaper •
    [Show full text]
  • Automated DNA Sequencing
    Automated DNA Sequencing Chemistry Guide ©Copyright 1998, The Perkin-Elmer Corporation This product is for research purposes only. ABI PRISM, MicroAmp, and Perkin-Elmer are registered trademarks of The Perkin-Elmer Corporation. ABI, ABI PRISM, Applied Biosystems, BigDye, CATALYST, PE, PE Applied Biosystems, POP, POP-4, POP-6, and Primer Express are trademarks of The Perkin-Elmer Corporation. AmpliTaq, AmpliTaq Gold, and GeneAmp are registered trademarks of Roche Molecular Systems, Inc. Centricon is a registered trademark of W. R. Grace and Co. Centri-Sep is a trademark of Princeton Separations, Inc. Long Ranger is a trademark of The FMC Corporation. Macintosh and Power Macintosh are registered trademarks of Apple Computer, Inc. pGEM is a registered trademark of Promega Corporation. Contents 1 Introduction. 1-1 New DNA Sequencing Chemistry Guide . 1-1 Introduction to Automated DNA Sequencing . 1-2 ABI PRISM Sequencing Chemistries . 1-5 PE Applied Biosystems DNA Sequencing Instruments . 1-7 Data Collection and Analysis Settings . 1-12 2 ABI PRISM DNA Sequencing Chemistries . 2-1 Overview . 2-1 Dye Terminator Cycle Sequencing Kits . 2-2 Dye Primer Cycle Sequencing Kits . 2-8 Dye Spectra . 2-12 Chemistry/Instrument/Filter Set Compatibilities . 2-13 Dye/Base Relationships for Sequencing Chemistries . 2-14 Choosing a Sequencing Chemistry. 2-15 3 Performing DNA Sequencing Reactions . 3-1 Overview . 3-1 DNA Template Preparation . 3-2 Sequencing PCR Templates . 3-10 DNA Template Quality. 3-15 DNA Template Quantity. 3-17 Primer Design and Quantitation . 3-18 Reagent and Equipment Considerations. 3-20 Preparing Cycle Sequencing Reactions . 3-21 Cycle Sequencing . 3-27 Preparing Extension Products for Electrophoresis .
    [Show full text]
  • Document Title: Development and Evaluation of a Whole Genome Amplification Method for Accurate Multiplex STR Genotyping of Compromised Forensic Casework Samples
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Development and Evaluation of a Whole Genome Amplification Method for Accurate Multiplex STR Genotyping of Compromised Forensic Casework Samples Author: Tracey Dawson Cruz, Ph.D. Document No.: 227501 Date Received: July 2009 Award Number: 2005-DA-BX-K002 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. FINAL TECHNICAL REPORT Development and Evaluation of a Whole Genome Amplification Method for Accurate Multiplex STR Genotyping of Compromised Forensic Casework Samples NIJ Award #: 2005-DA-BX-K002 Author: Tracey Dawson Cruz 1 This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S.
    [Show full text]
  • List of SARS-Cov-2 Diagnostic Test Kits and Equipments Eligible For
    Version 33 2021-09-24 List of SARS-CoV-2 Diagnostic test kits and equipments eligible for procurement according to Board Decision on Additional Support for Country Responses to COVID-19 (GF/B42/EDP11) The following emergency procedures established by WHO and the Regulatory Authorities of the Founding Members of the GHTF have been identified by the QA Team and will be used to determine eligibility for procurement of COVID-19 diagnostics. The product, to be considered as eligible for procurement with GF resources, shall be listed in one of the below mentioned lists: - WHO Prequalification decisions made as per the Emergency Use Listing (EUL) procedure opened to candidate in vitro diagnostics (IVDs) to detect SARS-CoV-2; - The United States Food and Drug Administration’s (USFDA) general recommendations and procedures applicable to the authorization of the emergency use of certain medical products under sections 564, 564A, and 564B of the Federal Food, Drug, and Cosmetic Act; - The decisions taken based on the Canada’s Minister of Health interim order (IO) to expedite the review of these medical devices, including test kits used to diagnose COVID-19; - The COVID-19 diagnostic tests approved by the Therapeutic Goods Administration (TGA) for inclusion on the Australian Register of Therapeutic Goods (ARTG) on the basis of the Expedited TGA assessment - The COVID-19 diagnostic tests approved by the Ministry of Health, Labour and Welfare after March 2020 with prior scientific review by the PMDA - The COVID-19 diagnostic tests listed on the French
    [Show full text]
  • Rutgers Clinical Genomics Laboratory Taqpath SARS-Cov-2 Assay EUA Summary
    Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay EUA Summary ACCELERATED EMERGENCY USE AUTHORIZATION (EUA) SUMMARY SARS-CoV-2 ASSAY (Rutgers Clinical Genomics Laboratory) For in vitro diagnostic use Rx only For use under Emergency Use Authorization (EUA) Only (The Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay will be performed in the Rutgers Clinical Genomics Laboratory, a Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a certified high-complexity laboratory, per the Instructions for Use that were reviewed by the FDA under this EUA). INTENDED USE The Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay is a real-time reverse transcription polymerase chain reaction (rRT-PCR) test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in oropharyngeal (throat) swab, nasopharyngeal swab, anterior nasal swab, mid-turbinate nasal swab, and bronchoalveolar lavage (BAL) fluid from individuals suspected of COVID-19 by their healthcare provider. This test is also for use with saliva specimens that are self-collected at home or in a healthcare setting by individuals using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device when determined to be appropriate by a healthcare provider. Testing is limited to Rutgers Clinical Genomics Laboratory (RCGL) at RUCDR Infinite Biologics – Rutgers University, Piscataway, NJ, that is a Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a certified high-complexity laboratory. Results are for the detection and identification of SARS-CoV-2 RNA. The SARS- CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection.
    [Show full text]
  • DNA Fragment Analysis by Capillary Electrophoresis User Guide
    USER GUIDE DNA Fragment Analysis by Capillary Electrophoresis Publication Number 4474504 Revision B For Research Use Only. Not intended for use in diagnostic procedures. For Research Use Only. Not intended for use in diagnostic procedures. The information in this guide is subject to change without notice. DISCLAIMER LIFE TECHNOLOGIES CORPORATION AND/OR ITS AFFILIATE(S) DISCLAIM ALL WARRANTIES WITH RESPECT TO THIS DOCUMENT, EXPRESSED OR IMPLIED, INCLUDING BUT NOT LIMITED TO THOSE OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. TO THE EXTENT ALLOWED BY LAW, IN NO EVENT SHALL LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) BE LIABLE, WHETHER IN CONTRACT, TORT, WARRANTY, OR UNDER ANY STATUTE OR ON ANY OTHER BASIS FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING BUT NOT LIMITED TO THE USE THEREOF. TRADEMARKS All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. AmpErase, AmpliTaq, AmpliTaq Gold, and TaqMan are registered trademarks of Roche Molecular Systems, Inc. AFLP is a registered trademark of Keygene N.V. Millipore is a registered trademark of Merck KGaA. © 2014 Thermo Fisher Scientific Inc. All rights reserved. Contents About This Guide . 13 Revision history . 13 Purpose . 13 Prerequisites . 13 Structure of this guide . 14 ■ CHAPTER 1 Introduction to Fragment Analysis . 15 Fragment analysis versus sequencing…what is the difference? . 15 Fragment analysis . 15 Sequencing . 16 What can I do with fragment analysis? . 16 Types of applications . 16 Applications described in this guide . 17 What is capillary electrophoresis? . 18 Fragment analysis workflow . 19 ■ CHAPTER 2 Experimental Design .
    [Show full text]
  • Supporting Information Supplementary Methods
    Supporting Information Supplementary methods This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Caly L, Druce J, Roberts J, et al. Isolation and rapid sharing of the 2019 novel coronavirus (SAR-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med J Aust 2020; doi: 10.5694/mja2.50569. Supplementary methods 1.1 Generation of SARS-CoV-2 cDNA 200μL aliquots from swab (nasopharyngeal in VTM), sputum, urine, faeces and serum samples were subjected to RNA extraction using the QIAamp 96 Virus QIAcube HT Kit (Qiagen, Hilden, Germany) and eluted in 60μL. Reverse transcription was performed using the BioLine SensiFAST cDNA kit (Bioline, London, United Kingdom), total reaction mixture (20μL), containing 10μL RNA extract, 4μL 5x TransAmp buffer, 1μL reverse transcriptase and 5μL nuclease-free water. The reactions were incubated at 25°C for 10 min, 42°C for 15 min and 85°C for 5 min. 1.2 Nested SARS-CoV-2 RT-PCR and Sanger sequencing A PCR mixture containing 2μL cDNA, 1.6 μl 25mM MgCl2, 4μL 10x Qiagen Taq Buffer, 0.4μL 20mM dNTPs, 0.3μL Taq polymerase (Qiagen, Hilden, Germany) and 2μL of 10 μM primer pools as described2. Briefly, first round included the forward (5'-GGKTGGGAYTAYCCKAARTG-3') and reverse (5'-GGKTGGGAYTAYCCKAARTG-3') primers. Cycling conditions were 94°C for 10min, followed by 30 cycles of 94°C for 30s, 48°C for 30s and 72°C for 40s, with a final extension of 72°C for 10 min.
    [Show full text]
  • Applied Biosystems 3130 and 3130Xl Genetic Analyzers
    System Profile Applied Biosystems 3130 and 3130xl Genetic Analyzers. System Profile Applied Biosystems 3130 and 3130xl Genetic Analyzers Table of Contents A Powerful Blend of Flexibility and Performance 1 Ease-of-Use 1 Key Features 2 Capillary Electrophoresis 2 Automated Polymer Delivery System 2 Enhanced Thermal Control 2 High-Perfomance Capillaries and Electro-osmotic Flow Suppression (EOF) Polymers 2 Detection Method Designed for Sensitivity 3 Spectral Array Detection 3 Application Flexibility 4 Complete System Optimized for Multiple Applications 4 One Polymer, One Array, Maximum Performance 4 System Software Suite 5 Results 6 Summary 9 References 10 www.appliedbiosystems.com 16-capillary 3130xl Genetic Analyzer: High-performance workhorse. With 16-capillary throughput and advanced automation capabilities, the 3130xl system is flexible enough to meet the throughput needs of the busiest core facility or research group. The streamlined set-up and 24-hour unattended operation make it an ideal choice for low or medium throughput laboratories. Ease-of-Use Complete automation. At every scale, Applied Biosystems genetic analyzers are known for their advanced automation and “hands-free” operation. The Automated Polymer Delivery System A Powerful Blend of Flexibility and Performance eliminates manual washing and filling of polymer syringes, Applied Biosystems has a long tradition of providing significantly reducing the time required for instrument set- excellence in life science instruments, reagents, and software. up and maintenance. All steps are automated, including This tradition of pioneering and innovation in the field polymer loading, sample injection, separation and detection, of genetic analysis continues with the introduction of and data analysis. After placing plates on the autosampler Applied Biosystems next-generation systems, the 3130 and importing sample information, just select the “Start and 3130xl Genetic Analyzers.
    [Show full text]
  • Polymerase Chain Reaction Assay for Detection and Identity of Extraneous Chicken Anemia Virus (CAV)
    VIRPRO0118.05 Page 1 of 13 United States Department of Agriculture Center for Veterinary Biologics Testing Protocol Polymerase Chain Reaction Assay for Detection and Identity of Extraneous Chicken Anemia Virus (CAV) Date: September 25, 2014 Number: VIRPRO0118.05 Supersedes: VIRPRO0118.04, June 28, 2011 Contact: Sandra K. Conrad, (515) 337-7200 Danielle M. Koski Approvals: /s/Geetha B. Srinivas Date: 13Nov14 Geetha B. Srinivas, Section Leader Virology /s/Rebecca L.W. Hyde Date: 18Nov14 Rebecca L.W. Hyde, Section Leader Quality Management Center for Veterinary Biologics United States Department of Agriculture Animal and Plant Health Inspection Service P. O. Box 844 Ames, IA 50010 Mention of trademark or proprietary product does not constitute a guarantee or warranty of the product by USDA and does not imply its approval to the exclusion of other products that may be suitable. UNCONTROLLED COPY Center for Veterinary Biologics VIRPRO0118.05 Testing Protocol Page 2 of 13 Polymerase Chain Reaction Assay for Detection and Identity of Extraneous Chicken Anemia Virus (CAV) Table of Contents 1. Introduction 2. Materials 2.1 Equipment/instrumentation 2.2 Reagents/supplies 3. Preparation for the Test 3.1 Personnel qualifications/training 3.2 Preparation of equipment/instrumentation 3.3 Preparation of reagents/control procedures 3.4 Storage of the sample 4. Performance of the Test 4.1 DNA extraction 4.2 Amplification of CAV DNA 4.3 Analysis of amplified CAV DNA 5. Interpretation of the Test Results 6. Report of Test Results 7. Summary of Revisions UNCONTROLLED COPY Center for Veterinary Biologics VIRPRO0118.05 Testing Protocol Page 3 of 13 Polymerase Chain Reaction Assay for Detection and Identity of Extraneous Chicken Anemia Virus (CAV) 1.
    [Show full text]
  • Brochure: Biotech Essentials
    High-performance, flexible and reliable products that will set you up for success thermofisher.com/biotechessentials Techniques like cell growth, modification and analysis, sample preparation, PCR, qPCR, sequencing, electrophoresis and western blotting are the building blocks of your projects. Getting these fundamentals right first-time is critical to you moving quickly and efficiently towards your end goal. In order to do this, you need a partner who can supply all the right products and services. They need to be reliable, flexible, scalable and save you time so that you can minimise development and product costs, reduce risk, and reach your next milestone faster. We have a whole range of solutions dedicated to serving these needs ranging from off-the-shelf and customisable reagents and instruments to outsourcing services and manufacturing solutions. Take a look through this brochure to find out more. We’ll work with you every step of the way to ensure you’re set for success. Cell growth, scale-up and modification 4 Cellular analysis 6 Cellular analysis screening 8 Sample preparation 10 Synthetic biology 12 PCR 14 Electrophoresis 16 RNA extraction and cDNA synthesis for qPCR 17 Real-time PCR 18 Sanger and next-generation sequencing 20 Protein analysis 22 Outsourcing services 25 Custom manufacturing and commercial supply 26 Opening a new lab or relocating? 28 3 Cell Growth, Scale-up and Modification Whether you are culturing or modifying your cells, our range of Gibco™, Thermo Scientific™ Nunc™ and Invitrogen™ products will deliver the quality, consistency and performance you need at every step of your journey from discovery to commercialisation.
    [Show full text]
  • Relative Quantification Getting Started Guide for the Applied Biosystems 7300/7500/7500 Fast Real-Time PCR System RQ Experiment Workflow
    Getting Started Guide Relative Quantification Introduction and Example Applied Biosystems 7300/7500/7500 Fast RQ Experiment Real-Time PCR System Designing an RQ Experiment Performing Primer Extended on mRNA 5′ 3′ 5′ cDNA Reverse Primer Oligo d(T) or random hexamer Reverse Synthesis of 1st cDNA strand 3′ 5′ cDNA Transcription Generating Data from STANDARD RQ Plates - Standard Generating Data from FAST RQ Plates - Fast System Generating Data in an RQ Study © Copyright 2004, Applied Biosystems. All rights reserved. For Research Use Only. Not for use in diagnostic procedures. Authorized Thermal Cycler This instrument is an Authorized Thermal Cycler. Its purchase price includes the up-front fee component of a license under United States Patent Nos. 4,683,195, 4,683,202 and 4,965,188, owned by Roche Molecular Systems, Inc., and under corresponding claims in patents outside the United States, owned by F. Hoffmann-La Roche Ltd, covering the Polymerase Chain Reaction ("PCR") process to practice the PCR process for internal research and development using this instrument. The running royalty component of that license may be purchased from Applied Biosystems or obtained by purchasing Authorized Reagents. This instrument is also an Authorized Thermal Cycler for use with applications licenses available from Applied Biosystems. Its use with Authorized Reagents also provides a limited PCR license in accordance with the label rights accompanying such reagents. Purchase of this product does not itself convey to the purchaser a complete license or right to perform the PCR process. Further information on purchasing licenses to practice the PCR process may be obtained by contacting the Director of Licensing at Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404.
    [Show full text]
  • Real-Time Fluorescent RT-PCR Kit for Detecting SARS-Cov-2
    Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 For Emergency Use Only Instructions for Use (50 reactions/kit) For in vitro Diagnostic (IVD) Use Rx Only Labeling Revised: January XX, 2021 BGI Genomics Co. Ltd. (“BGI”) Building No. 7, BGI Park No. 21 Hongan 3rd Street Yantian District, Shenzhen, 518083 China, (+86) 400-706-6615 1 Table of Contents Table of Contents ................................................................................................................... 2 Intended Use ......................................................................................................................... 3 Summary and Explanation ....................................................................................................... 4 Principles and Procedure ......................................................................................................... 5 Materials Provided ................................................................................................................. 6 Materials and Equipment Required But Not Provided .................................................................. 7 Warnings and Precautions........................................................................................................ 8 Reagent Storage, Handling, and Stability ..................................................................................11 Specimen Collection, Storage, and Transfer ..............................................................................12 Laboratory Procedures ...........................................................................................................13
    [Show full text]